Ipilimumab
- Generic Name
- Ipilimumab
- Brand Names
- Yervoy
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 477202-00-9
- Unique Ingredient Identifier
- 6T8C155666
- Background
Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes. Ipilimumab was developed by Bristol-Myers Squibb and Medarex.
Ipilimumab was granted FDA approval on 25 March 2011.
- Indication
Ipilimumab is indicated in the following cancerous conditions:
Melanoma
Renal Cell Carcinoma (RCC)
Colorectal Cancer
Hepatocellular Carcinoma
Non-Small Cell Lung Cancer (NSCLC)
Malignant Pleural Mesothelioma
Esophageal Cancer
- Treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma, as first line treatment in combination with nivolumab
- Associated Conditions
- Cutaneous Melanoma, Hepatocellular Carcinoma, Metastatic Esophageal Squamous Cell Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Microsatellite Instability High Metastatic Colorectal Cancer (CRC), Mismatch Repair-deficient (dMMR) Metastatic Colorectal Cancer (CRC), Recurrent Non-small Cell Lung Cancer, Unresectable Melanoma, Poor or intermediate risk Advanced Renal Cell Carcinoma (aRCC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable, advanced Esophageal Squamous Cell Carcinoma (ESCC)
- Associated Therapies
- First Line Chemotherapy
Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced Melanoma
- First Posted Date
- 2017-01-27
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 94
- Registration Number
- NCT03033576
- Locations
- 🇺🇸
Kaiser Permanente-Fresno, Fresno, California, United States
🇺🇸Kaiser Permanente-Irvine, Irvine, California, United States
🇺🇸City of Hope Antelope Valley, Lancaster, California, United States
A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-01-20
- Last Posted Date
- 2020-07-17
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 42
- Registration Number
- NCT03026166
- Locations
- 🇺🇸
University Cancer & Blood Cent /ID# 161028, Athens, Georgia, United States
🇺🇸University of Chicago /ID# 161006, Chicago, Illinois, United States
🇪🇸Clinica Universitar de Navarra - Pamplona /ID# 165165, Pamplona, Navarra, Comunidad, Spain
Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-01-20
- Last Posted Date
- 2024-04-18
- Lead Sponsor
- The Netherlands Cancer Institute
- Target Recruit Count
- 268
- Registration Number
- NCT03026140
- Locations
- 🇳🇱
Marieke van de Belt, Amsterdam, Netherlands
🇳🇱Catharina Ziekenhuis, Eindhoven, Netherlands
🇳🇱Spaarne Ziekenhuis, Haarlem, Netherlands
PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas
- Conditions
- Interventions
- First Posted Date
- 2017-01-06
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- CytomX Therapeutics
- Target Recruit Count
- 300
- Registration Number
- NCT03013491
- Locations
- 🇬🇧
PROCLAIM Invetigative Site, Glasgow, United Kingdom
🇬🇧PROCLAIM Investigative Site, Newcastle upon Tyne, United Kingdom
🇪🇸PROCLAIM Investigative Ssite, Valencia, Spain
Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer
- First Posted Date
- 2017-01-04
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Immodulon Therapeutics Ltd
- Target Recruit Count
- 2
- Registration Number
- NCT03009058
- Locations
- 🇫🇷
Centre Léon Bérard, Dpt Medecine & INSERM, Lyon, France
🇫🇷Gustave Roussy Cancer Center, Villejuif, France
🇬🇧St George's University of London, Institute of Infection and Immunity, London, United Kingdom
ImmunoModulation by the Combination of Ipilimumab and Nivolumab Neoadjuvant to Surgery In Advanced or Recurrent Head and Neck Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2016-12-28
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- The Netherlands Cancer Institute
- Target Recruit Count
- 33
- Registration Number
- NCT03003637
- Locations
- 🇳🇱
NKI-AVL, Amsterdam, Noord-Holland, Netherlands
A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer
- First Posted Date
- 2016-12-06
- Last Posted Date
- 2022-11-01
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 211
- Registration Number
- NCT02982954
- Locations
- 🇺🇸
Los Angeles Cancer Network, Los Angeles, California, United States
🇺🇸Tennessee Oncology, PLLC - SCRI - PPDS, Chattanooga, Tennessee, United States
🇺🇸Hollings Cancer Center, Charleston, South Carolina, United States
A Phase II of Nivolumab Plus Ipilimumab in Non-resectable Sarcoma and Endometrial Carcinoma
- First Posted Date
- 2016-12-05
- Last Posted Date
- 2017-11-01
- Lead Sponsor
- Assaf-Harofeh Medical Center
- Target Recruit Count
- 60
- Registration Number
- NCT02982486
A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab
- Conditions
- Interventions
- First Posted Date
- 2016-12-01
- Last Posted Date
- 2024-04-04
- Lead Sponsor
- Georgetown University
- Target Recruit Count
- 14
- Registration Number
- NCT02978443
- Locations
- 🇺🇸
Washington Cancer Institute at MedStar Washington Hospital Center, Washington, District of Columbia, United States
🇺🇸John Theurer Cacner Center at Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States
Optimal Neo-adjuvant Combination Scheme of Ipilimumab and Nivolumab
- Conditions
- Interventions
- First Posted Date
- 2016-11-30
- Last Posted Date
- 2023-11-15
- Lead Sponsor
- The Netherlands Cancer Institute
- Target Recruit Count
- 186
- Registration Number
- NCT02977052
- Locations
- 🇦🇺
Melanoma Institute Australia, Sydney, New South Wales, Australia
🇳🇱Netherlands Cancer Institute, Amsterdam, NH, Netherlands
🇦🇹Medical University of Vienna, Vienna, Austria
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.